Dextroamphetamine/Amphetamine National Contract
ID: SPE2D17D0061P00006Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES (6515)

Original Source

https://sam.gov/opp/9704ca569b094cc890b8d594b05e366d/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is being modified to incorporate additional clauses to the contract.

    Dextroamphetamine/Amphetamine is a medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy.

    Please ensure the summary is concise and includes important entities such as locations, quantities, fulfillment requirements, sizes, etc.

    Point(s) of Contact
    denise taubman
    (215) 737-8677
    denise.taubman@dla.mil
    Files
    Title
    Posted
    SPE2D217D0061P00006 signed.pdf
    Lifecycle
    Title
    Type
    Dextroamphetamine/Amphetamine National Contract
    Currently viewing
    Special Notice
    Similar Opportunities
    Dextroamphetamine/Amphetamine National Contract
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is a procurement notice from the DEFENSE LOGISTICS AGENCY, specifically the DLA TROOP SUPPORT office. This notice falls under the category of MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES with a PSC code of 6515. The primary contact for this contract is Denise Taubman, who can be reached at DENISE.TAUBMAN@DLA.MIL or 215-737-8677. The notice describes an amendment, P00006, which incorporates additional clauses to the existing contract.
    Dextroamphetamine/Amphetamine National Contract
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is being modified to change the address for Acetris. This contract is related to the procurement of medical and surgical instruments, equipment, and supplies. The place of performance for this contract is Monmouth Junction, NJ 08852, USA. For more information, please contact Denise Taubman at denise.taubman@dla.mil or 215-737-8677.
    SPE2D220R0063 BUPROPION XL AMENDMENT 0002
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking BUPROPION XL. This procurement is for drugs and biologicals under PSC code 6505. The primary contact for this procurement is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778) and the secondary contact is Denise Taubman (denise.taubman@dla.mil, 2157376877). The notice includes Amendment 0002, which incorporates telecommunication clauses. The solicitation is not reopened and the closing date is not extended. BUPROPION XL is typically used for medical purposes.
    Fexofenadine HCL Follow On MOD P00002
    Active
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Fexofenadine HCL Follow On MOD P00001. Fexofenadine HCL is a drug used to relieve symptoms of seasonal allergies such as runny nose, sneezing, itchy or watery eyes, and itching of the nose or throat. This procurement is for NDC changes. For more information, please contact Catherine Gilbert at catherine.gilbert@dla.mil or 2157374778.
    LANSOPRAZOLE NATIONAL CONTRACT MODIFICATION
    Active
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is issuing a modification to the LANSOPRAZOLE NATIONAL CONTRACT. This modification aims to incorporate additional clauses to the existing contract. Lansoprazole is a medication used to treat stomach and esophagus problems such as acid reflux, ulcers, and gastroesophageal reflux disease (GERD). It belongs to a class of drugs known as proton pump inhibitors and helps reduce the amount of acid produced in the stomach. The modification to the contract will include the addition of specific clauses that may address various aspects such as pricing, delivery schedules, quality control, or any other relevant terms and conditions. For more information or inquiries, please contact Denise Taubman at DENISE.TAUBMAN@DLA.MIL or 2157378677.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Norgestimate/Ethinyl Estradiol Oral Tablets
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is modifying contract SPE2D220D0090 to correct an administrative error for the procurement of Norgestimate/Ethinyl Estradiol Oral Tablets. Norgestimate/Ethinyl Estradiol Oral Tablets are typically used for contraception and hormone replacement therapy.
    Pramipexole Tablets
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for Pramipexole Tablets under solicitation number SPE2D2-24-R-0017. This procurement aims to acquire pharmaceutical products, specifically Pramipexole in various dosages, to support military health needs. The solicitation outlines detailed requirements for offerors, including submission instructions via the Defense Logistics Agency Internet Bid Board System (DIBBS), compliance with federal regulations, and the necessity for performance assessments and ethical conduct. Interested contractors should reach out to Ryan Guarnere at Ryan.Guarnere@dla.mil or Jason Wray at jason.wray@dla.mil for further information regarding the submission process and compliance requirements.
    Lamotrigine
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Lamotrigine ER Tablets, specifically in dosages of 25MG, 50MG, 100MG, 200MG, 250MG, and 300MG, packaged in 30 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for various Department of Defense and other federal health service customers, including the Bureau of Prisons and the Department of Veterans Affairs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should prepare for the solicitation, projected for November 2024, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or by phone at 215-737-4955.
    Fluconazole - Modification P00005 to Contract
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY - TROOP SUPPORT MEDICAL is seeking a modification to the contract for Fluconazole. Fluconazole is a medication used to treat and prevent fungal infections. The modification, P00005, will involve changing the National Drug Codes (NDCs) associated with the procurement.